Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction
Launched by BOSTON SCIENTIFIC CORPORATION · Jul 9, 2008
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 years or older
- • Inoperable extrahepatic biliary obstruction by any malignant process
- • Indicated for metal stent placement for palliative treatment of biliary stricture(s) produced by malignant neoplasms
- • Willing and able to comply with the study procedures and provide written informed consent to participate in the study
- Exclusion Criteria:
- • Participation in another invesitgational study within 90 days prior to date of patient consent.
- • Strictures that cannot be dialated enough to pass the delivery system
- • Perforation of any duct within the biliary tree
- • Presence of any esophageal or duodenal stent
- • Patients for whom endoscopic procedures are contraindicated
- • Patients with known senesitivity to any components of the stent or delivery system
- • Patients with active hepatitis
About Boston Scientific Corporation
Boston Scientific Corporation is a global leader in medical device innovation, dedicated to providing solutions that enhance patient care and improve clinical outcomes. With a strong focus on advancing the treatment of various medical conditions, Boston Scientific develops and manufactures a diverse range of products across multiple specialties, including cardiology, urology, and endoscopy. The company is committed to rigorous clinical research and development, ensuring that its devices meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and ongoing investment in technology and education, Boston Scientific strives to deliver breakthrough therapies that address unmet medical needs and empower patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rome, , Italy
Brussels, , Belgium
Lyon, Cedex 3, France
Dusseldorf, , Germany
Hyderabaad, , India
Amsterdam, Az, Netherlands
Patients applied
Trial Officials
Robert Walsh, M.D.
Study Director
Boston Scientific Corporation
Guido Costamagna, M.D.
Principal Investigator
Università Cattolica del Sacro Cuore, Policlinico A. Gemelli
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials